A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: reconsider (13), check (1000)

UHS adult major trauma guidelines

Description
Adult Major Trauma Guidelines University Hospital Southampton NHS Foundation Trust Dr Mark Baxter Director of Major Trauma, Consultant in O
Url
/Media/SUHTExtranet/WessexTraumaNetwork/UHS-adult-major-trauma-guidelines.pdf

Papers Trust Board - 5 November 2024

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 05/11/2024 9:00 - 11:30 The Ark Conference Centre
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-5-November-2024.pdf

CRF Assistant Project Manager_Study Manager JD 15 11 2023

Description
Post Title: Agenda for Change: Job Description BRC Assistant Project Manager/Study Manager Directorate/Department: Trust Headquarters NI
Url
/Media/Southampton-Clinical-Research/Downloads/CRF-Assistant-Project-Manager-Study-Manager-JD-15-11-2023.pdf

Apalutamide v1

Description
Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Fluorouracil-Folinic Acid-Irinotecan-Oxaliplatin

Description
Chemotherapy Protocol PANCREATIC CANCER FLUOROURACIL-FOLINIC ACID-IRINOTECAN-OXALIPLATIN (FOLFIRINOX) This protocol may require funding
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Pancreas/Fluorouracil-Folinic-Acid-Irinotecan-Oxaliplatin.pdf

Erdafitinib

Description
Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unrese
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

Annual-report-2018-19

Description
ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Annual report 2021-2022

Description
2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

VenetoclaxLow

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf
11 to 20 of 38
Previous 1 2 3 4 Next